Tirzepatide injection maka ọrịa shuga na mbelata ibu

Tirzepatide bụ akwụkwọ akụkọ abụọ na-adabere na insulinotropic polypeptide (GIP) na glucagon-dị ka peptide-1 (GLP-1) agonist nnabata. Usoro ya abụọ na-achọ ịkwalite mmepụta insulin, na-egbochi mwepụta glucagon, igbu oge ịwụsa afọ, ma melite satiety, na-enye usoro ọgwụgwọ zuru oke maka ụdị ọrịa shuga mellitus 2 (T2DM) na oke ibu.

Ihe nchọpụta dị mkpa sitere na ọmụmụ ụlọ ọgwụ

1. Njikwa glycemic

N'ofe otutuỌkachamaraNkeji 3 nyocha ụlọ ọgwụ, tirzepatide gosipụtaranjikwa glycemic dị eluma e jiri ya tụnyere ọgwụ antidiabetic dị ugbu a, gụnyere semaglutide na insulin degludec.

• Mbelata HbA1c pụtara: ruo-2.4%site na ntọala mgbe izu 40-52 gasịrị.

• Ọnụ ọgụgụ dị elu nke ndị sonyere nwetaraHbA1c <6.5%, izute ma ọ bụ karịa ebumnuche ADA.

• Achọpụtara mmụba dị ịrịba ama na ọkwa glucose plasma na-ebu ọnụ na ọkwa glucose postprandial.

2. Mbelata ibu

A na-emepụta Tirzepatide mgbe niileClinically bara uru na dose-adabere arọ ọnwụna ma ndị ọrịa mamịrị ma ndị na-abụghị ndị ọrịa mamịrị.

• Na ndị ọrịa T2DM: nkezi mbelata ịdị arọ ahụ sitere na7-12 n'arọ.

• N'ime ihe ndị na-abụghị ọrịa shuga (nnwale SURMOUNT-1):

  • 10 mg na 15 mg doses butere15-22% pụtara ọnwụ anụ ahụ, tụnyere ma ọ bụ gafere oke ịwa ahụ bariatric.

• Ọtụtụ ndị sonyere rụzuru opekata mpe5-10%mbelata ibu.

3. Mmezi Cardiometabolic

Ọgwụgwọ Tirzepatide mekwara ka parampat metabolic sara mbara karị:

• Mbelatana triglycerides, LDL-C, na mkpokọta cholesterol.

• Na-abawanyena HDL-C.

• Dị mkpambelata nke systolic na diastolic ọbara mgbali.

• Ọganihu na mmetụta insulin na ọrụ β-cell.

4. Nchekwa na ndidi

Profaịlụ nchekwa ahụ dabara na usoro ọgwụgwọ dabere incretin ndị ọzọ:

• Ihe na-adịghị mma na-emekarị: mgbaàmà eriri afọ na-adị nwayọọ ruo na-agafeghị oke (ọgbụgbọ, vomiting, afọ ọsịsa).

• Mmụba dị ala nke hypoglycemia, ọkachasị mgbe ejiri insulin ma ọ bụ sulfonylureas mee ihe.

• Enweghị nnukwu nchegbu nchekwa ahụrụ na nsonaazụ obi.

5. Mechanistic Nghọta

Tirzepatide pụrụ icheabụọ receptor agonismna-abawanye ma ụzọ GIP na GLP-1:

• GIP ịgbalitena-akwalite mmepụta insulin dabere na glucose ma nwee ike melite metabolism anụ ahụ adipose.

• GLP-1 ịgbalitena-akwalite mbelata agụụ ma na-egbu oge imefusị afọ.

• Hammetụta synergisticna-eduga n'ịchịkwa glucose ka mma yana mbelata ịdị arọ dị elu ma e jiri ya tụnyere ndị na-eme otu ụzọ.

Mmechi

Tirzepatide na-anọchite anya aọganihu na usoro ọgwụgwọ metabolic, inyearụmọrụ na-enwetụbeghị ụdị ya na njikwa glycemic na mbelata ibumaka ndị nwere ụdị ọrịa shuga 2 na oke ibu.
Usoro incretin ya abụọ na-enye usoro njikọ chiri anya na-agwa isi ihe na-akpata dysfunction metabolic - hyperglycemia, nguzogide insulin, na oke ahụ.
N'iburu n'ọrụ ya siri ike yana profaịlụ nchekwa enwere ike ijikwa ya, tirzepatide nwere ike ịkọwapụta usoro ọgwụgwọ maka ọrịa shuga na njikwa oke ibu n'ime afọ iri na-abịanụ.

Ntụaka

• Frias JP et al.,Akwụkwọ akụkọ Ọgwụ nke New England, 2021.

• Jastreboff AM et al.,Akwụkwọ akụkọ Ọgwụ nke New England, 2022 (SURMOUNT-1).

• Ludvik B et al.,Lancet, 2021.

• Data Clinical Eli Lilly, Nnwale SURPASS 1–5.